Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RAJEEV KUMAR

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1447343751
CMS profile
337695
Location
ENGLEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$206,980.44

336 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 4 of 7; records 151–200 of 336 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RAJEEV KUMAR

NPI 1447343751 · CMS profile ID 337695

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

ENGLEWOOD, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 4 of 7; records 151–200 of 336 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447343751?year=2019&recipient=provider&page=4#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RAJEEV KUMAR, NPI 1447343751, CMS profile ID 337695. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 336 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447343751?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RAJEEV KUMAR, NPI 1447343751, CMS profile ID 337695. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 4 of 7; records 151–200 of 336 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447343751?year=2019&recipient=provider&page=4#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RAJEEV KUMAR, NPI 1447343751, CMS profile ID 337695, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 4 of 7; records 151–200 of 336 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1447343751?year=2019&recipient=provider&page=4#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

336 matching records · $206,980.44 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 336 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 151–200 of 336.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Adamas Pharmaceuticals, Inc. $16.6807/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694968595 CMS
Teva Pharmaceuticals USA, Inc. $12.1406/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697721209 CMS
Teva Pharmaceuticals USA, Inc. $0.3106/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697715849 CMS
US WorldMeds, LLC $10.0406/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699461034 CMS
ACADIA Pharmaceuticals Inc $3,250.0006/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700010963 CMS
US WorldMeds, LLC $266.9606/25/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699461015 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0006/21/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866139 CMS
Teva Pharmaceuticals USA, Inc. $0.9606/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697713845 CMS
Amneal Pharmaceuticals LLC $9.4306/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692317787 CMS
Neurocrine Biosciences, Inc. $20.1206/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693142261 CMS
Teva Pharmaceuticals USA, Inc. $9.9706/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697788485 CMS
Adamas Pharmaceuticals, Inc. $14.3906/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694968593 CMS
Acorda Therapeutics, Inc $26.9006/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498271 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0006/14/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866141 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0006/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866143 CMS
Teva Pharmaceuticals USA, Inc. $4,040.0006/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866153 CMS
Acorda Therapeutics, Inc $3,400.0006/12/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498269 CMS
ACADIA Pharmaceuticals Inc $95.6806/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700010961 CMS
ARBOR PHARMACEUTICALS, INC. $15.7906/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697346127 CMS
ACADIA Pharmaceuticals Inc $605.1806/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700010959 CMS
Acorda Therapeutics, Inc $37.0806/10/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498267 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0006/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866145 CMS
Acorda Therapeutics, Inc $1,700.0006/05/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498265 CMS
Acorda Therapeutics, Inc $17.2406/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498263 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0006/04/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866147 CMS
Retrophin, Inc. $0.8306/03/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701823167 CMS
AbbVie, Inc. $22.5705/31/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647792637 CMS
US WorldMeds, LLC $15.6105/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699461039 CMS
Allergan Inc. $15.6205/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670686589 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0005/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866149 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0005/24/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866151 CMS
Teva Pharmaceuticals USA, Inc. $13.1905/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697709633 CMS
Teva Pharmaceuticals USA, Inc. $0.1705/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697766475 CMS
Adamas Pharmaceuticals, Inc. $14.5205/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694968591 CMS
Amneal Pharmaceuticals LLC $16.2005/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 692317785 CMS
Teva Pharmaceuticals USA, Inc. $30.0005/16/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866247 CMS
Lundbeck LLC $21.4905/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684313083 CMS
Acorda Therapeutics, Inc $23.1905/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498261 CMS
Acorda Therapeutics, Inc $1,550.0005/10/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498259 CMS
ACADIA Pharmaceuticals Inc $85.2305/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 700010957 CMS
Acorda Therapeutics, Inc $900.0005/08/2019 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498257 CMS
Adamas Pharmaceuticals, Inc. $27.7505/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694968589 CMS
Retrophin, Inc. $0.8305/08/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701823169 CMS
Teva Pharmaceuticals USA, Inc. $2,020.0005/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866171 CMS
Teva Pharmaceuticals USA, Inc. $124.7405/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866253 CMS
Acorda Therapeutics, Inc $3,400.0005/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498253 CMS
Acorda Therapeutics, Inc $1,700.0005/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498255 CMS
Teva Pharmaceuticals USA, Inc. $3,030.0005/06/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 697866245 CMS
US WorldMeds, LLC $27.3005/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699461011 CMS
Acorda Therapeutics, Inc $1,700.0005/03/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 633498251 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $206,980.44 336
PY2020 $245,871.51 155
PY2021 $153,684.83 189
PY2022 $88,589.85 200
PY2023 $175,165.03 241
PY2024 $74,689.19 159
PY2025 $9,869.79 59

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $782,623.04 58
PY2024 Principal investigator $2,102,950.63 80
PY2023 Principal investigator $990,600.91 94
PY2022 Principal investigator $1,425,497.25 126
PY2021 Principal investigator $2,118,892.70 230
PY2020 Principal investigator $2,550,428.88 260
PY2019 Recipient $7,612.40 2
PY2019 Principal investigator $3,392,943.65 466

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

58 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 H. Lundbeck A S $5,481.90 12/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251778021
Principal investigator 1 Roche TCRC, Inc. $7,793.00 08/13/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584483
Principal investigator 1 H. Lundbeck A S $203.00 07/31/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251772926
Principal investigator 1 ABBVIE INC. $17,950.64 07/24/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202499680
Principal investigator 1 Genentech, Inc. $12,918.00 07/23/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CENTER PC
Ph2a of IZD334 in Parkinsons disease No dispute reported 06/30/2026 1211648192
Principal investigator 1 ABBVIE INC. $390.02 07/22/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202499128
Principal investigator 1 ABBVIE INC. $100.00 07/18/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202498928
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $889.00 07/01/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244051783
Principal investigator 1 Sage Therapeutics, LLC $1,040.72 06/27/2025 Non-covered Recipient Entity
CENEXEL IRESEARCH LLC
A Study to Evaluate the Effects of SAGE-718 in Participants With Parkinson's Disease Cognitive Impairment No dispute reported 06/30/2026 1206580761
Principal investigator 1 ABBVIE INC. $1,301.27 06/19/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202492429
Principal investigator 1 Eli Lilly and Company $100.00 06/13/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
AN OPEN-LABEL, DOSE-FINDING, PHASE 1/2 STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A SINGLE INTRAVENOUS DOSE OF LY3884961 IN PATIENTS WITH PERIPHERAL MANIFESTATIONS OF GAUCHER DISEASE (PROCEED) No dispute reported 06/30/2026 1187876607
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584446
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584448
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584453
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584456
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584459
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584462
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584466
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584470
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584473
Principal investigator 1 Genentech, Inc. $1,453.00 06/11/2025 Non-covered Recipient Entity
CenExel Rocky Mountain Clinical Research, LLC
Epidemiology Study No dispute reported 06/30/2026 1211584479
Principal investigator 1 ABBVIE INC. $2,050.00 05/22/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202485823
Principal investigator 1 Genentech, Inc. $8,500.00 04/29/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CENTER PC
Ph2a of IZD334 in Parkinsons disease No dispute reported 06/30/2026 1211648174
Principal investigator 1 H. Lundbeck A S $2,026.80 04/28/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251769890
Principal investigator 1 Sage Therapeutics, LLC $87,581.28 04/28/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CENTER, PC
A Study to Evaluate the Effect of SAGE-718 on Cognitive Function in Participants With Huntington's Disease (HD) No dispute reported 06/30/2026 1206580540
Principal investigator 1 ABBVIE INC. $1,573.43 04/17/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202477840
Principal investigator 1 H. Lundbeck A S $107.00 04/08/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251769467
Principal investigator 1 H. Lundbeck A S $3,455.10 04/08/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251769497
Principal investigator 1 ABBVIE INC. $1,605.25 04/04/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202474507
Principal investigator 1 ABBVIE INC. $997.82 04/03/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202473691
Principal investigator 1 Eli Lilly and Company $2,125.00 03/24/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN RESEARC
ASSESSMENT OF SAFETY AND EFFICACY OF INTRAVENOUS REMTERNETUG IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE No dispute reported 06/30/2026 1187878893
Principal investigator 1 Genentech, Inc. $170.00 03/20/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CENTER PC
Ph2a of IZD334 in Parkinsons disease No dispute reported 06/30/2026 1211648183
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $8,500.00 03/20/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA) No dispute reported 06/30/2026 1244051675
Principal investigator 1 ABBVIE INC. $1,564.92 03/13/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202463827
Principal investigator 1 Eli Lilly and Company $150.00 03/12/2025 Non-covered Recipient Entity
COLLABORATIVE NEUROSCIENCE RESEARCH LLC
A PHASE 1/2A OPEN-LABEL ASCENDING DOSE STUDY TO EVALUATE THE SAFETY AND EFFECTS OF LY3884961 IN PATIENTS WITH PARKINSON'S DISEASE WITH AT LEAST ONE GBA1 MUTATION (PROPEL) No dispute reported 06/30/2026 1187882270
Principal investigator 1 H. Lundbeck A S $2,026.80 03/11/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251768608
Principal investigator 1 UCB SA $6,508.12 03/07/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN
A dose-blinded extension study to evaluate the long-term efficacy, safety, and tolerability of UCB0599 in study participants with Parkinsons disease No dispute reported 06/30/2026 1246659058
Principal investigator 1 ABBVIE INC. $6,419.80 03/06/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202459075
Principal investigator 1 PTC Therapeutics, Inc. $2,250.00 02/27/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OFPTC518IN SUBJECTS WITH HUNTINGTON'S DISEASE No dispute reported 06/30/2026 1249093229
Principal investigator 1 ABBVIE INC. $150.00 02/20/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202453004
Principal investigator 1 Roche TCRC, Inc. $1,656.52 02/20/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CTR
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211648202
Principal investigator 1 ABBVIE INC. $3,000.00 02/13/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Fixed-Dose Trial in Early Parkinson s Disease (PD) (TEMPO-1) No dispute reported 06/30/2026 1202451865
Principal investigator 1 Sage Therapeutics, LLC $14,537.35 02/06/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Study to Evaluate the Long-term Safety and Tolerability of SAGE-324 in Participants With Essential Tremor No dispute reported 06/30/2026 1206580823
Principal investigator 1 ABBVIE INC. $3,175.20 02/05/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL
M20-098 - Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson Disease No dispute reported 06/30/2026 1202445011
Principal investigator 1 H. Lundbeck A S $2,026.80 02/05/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766975
Principal investigator 1 Sage Therapeutics, LLC $99,210.42 02/05/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Huntington's Disease No dispute reported 06/30/2026 1206580985
Principal investigator 1 UCB SA $6,853.00 02/05/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN
A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, 18-MONTH PHASE 2A STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ORAL UCB0599 IN STUDY PARTICIPANTS WITH EARLY Parkinsons DISEASE No dispute reported 06/30/2026 1246659100
Principal investigator 1 Genentech, Inc. $216,982.00 02/04/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CENTER PC
A Phase 2b efficacy safety trial of Prasinezumab in patients with early Parkinson s Disease No dispute reported 06/30/2026 1211648170
Principal investigator 1 Genentech, Inc. $1,844.00 01/28/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC CENEXEL RMCR
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211584442
Principal investigator 1 H. Lundbeck A S $251.00 01/23/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766663
Principal investigator 1 H. Lundbeck A S $535.00 01/23/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766668
Principal investigator 1 H. Lundbeck A S $2,093.40 01/17/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766550
Principal investigator 1 UCB SA $9,108.00 01/17/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246657978
Principal investigator 1 ABBVIE INC. $17,311.97 01/16/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Open-label Trial in Parkinson s Disease (PD) (TEMPO-4) No dispute reported 06/30/2026 1202439829
Principal investigator 1 Roche TCRC, Inc. $42,574.50 01/16/2025 Non-covered Recipient Entity
ROCKY MOUNTAIN MOVEMENT DISORDERS CTR
Phase II study in early stage Parkinson s Disease Patients No dispute reported 06/30/2026 1211648206
Principal investigator 1 Sage Therapeutics, LLC $14,253.21 01/16/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
Study to Evaluate SAGE-324 in Participants With Essential Tremors No dispute reported 06/30/2026 1206580302
Principal investigator 1 Genentech, Inc. $144,725.00 01/15/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC CENEXEL RMCR
Phase II dose finding study in prodromal early manifest HD individuals No dispute reported 06/30/2026 1211584438
Principal investigator 1 H. Lundbeck A S $2,026.80 01/07/2025 Non-covered Recipient Entity
CENEXEL ROCKY MOUNTAIN CLINICAL RESEARCH LLC
AMULET CLINICAL STUDY PHASE II (INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED) No dispute reported 06/30/2026 1251766216